DALLAS and NEW YORK, Dec. 10, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has entered into definitive agreements with existing and new accredited investors to sell, in a registered direct offering, an aggregate of approximately 2.3 million shares of its common stock at a price of$2.55 per share for aggregate gross proceeds of $6.0 million. Additionally, at the closing, Access will issue to the investors warrants to purchase, in the aggregate, approximately 0.7 million shares of common stock at a price of $3.06 per share, which warrants are exercisable immediately for a term of 5 years from the closing date. The initial closing of the offering is expected to take place subject to the satisfaction of customary closing conditions.
“In addition to providing Access capital to support the commercial launch of MuGard, this financing should prove to be a positive for Access investors as it also helps shore up our balance sheet for partnering discussions in our various programs,” stated Jeffrey B. Davis, President & CEO. He continued, “This additional funding from current and new investors will provide a strong foundation to continue executing on our multifaceted strategy for moving valuable assets within the company forward.”
Read more »
Company Gains Traction With Top Healthcare Insurance Companies Less Than Two Months Into Full-Scale Lead Product Launch
Dallas, TX and New York, NY, December 9, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has made significant progress in obtaining MuGard reimbursements from various third-party payer networks. Some of the national insurance reimbursements included several state plans from Blue Cross Blue Shield, Health Net, Caremark, Well Point Next Rx, Harvard Pilgrim and Medicaid.
Read more »
Significant Step Validates Company’s Unique Value-Driven Strategy For Exploiting Multi-applicable Oral Drug Delivery Technology Platform
Dallas, TX and New York, NY, December 08, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major global pharmaceutical company to test Access’ oral insulin formulation based upon its proprietary vitamin B-12-based CobOral™ Drug Delivery Technology. Access will provide CobOral insulin to the pharmaceutical company. Access anticipates completion and delivery of its CobOral insulin formulation to the pharmaceutical company by the end of the month.
Read more »
MuGard Website Features Video And Additional Written Clinician Feedback
Dallas, TX and New York, NY, December 3, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has updated its lead product website, www.MuGard.com, with its first patient MuGard experience testimonial video and additional clinician feedback.
The video can be found under the Testimonial section of the MuGard website (www.MuGard.com), or by clicking on the following link: www.MuGard.com/testimonials/.
Read more »
National Broadcast Television Program To Include Interview With Company’s Chairman
Dallas, TX and New York, NY, November 19, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that its Chairman, Steven Rouhandeh, will appear on WALLSTREETCAST, a national weekly television program airing on the FOX Business Network. The show will air tomorrow, Saturday, November 20th at 1:30 PM ET. The segment may also be viewed online at http://www.moneychannel.tv.
Read more »
Conference Hosted by the Cancer Prevention and Research Institute of Texas (CPRIT)
Dallas, TX and New York, NY, November 17, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX. The poster being displayed, entitled “Vitamin B-12 Nanoparticles for the Targeted Delivery of RNAi Therapeutics”, summarizes key findings of the Company’s rebranded Cobalamin program, CobaCyte for RNAi. The second poster, entitled “Preclinical and Clinical Studies of ProLindac: A Novel Polymer Prodrug of DACH Platinum”, details the distinct attributes and advantages of utilizing Access’ second generation DACH Platinum, ProLindac.
Read more »
Dallas, TX and New York, NY, November 11, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that it will be presenting a poster today at the 10th Annual Diabetes Technology Meeting, entitled, “Preclinical Studies with Cobalamin™ Nanoparticles for Oral Drug Delivery of Insulin.” The poster reviews the progress made by Access scientists in developing its proprietary oral insulin formulation. Access recently rebranded its oral drug delivery technology as CobOralTM to reflect the advances made with the technology platform.
Read more »
Chairman To Provide Update To Investors On Company’s Recent Developments
Dallas, TX and New York, NY, November 09, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that its Chairman, Steven Rouhandeh, will present at the 1st Annual LifeTech Capital Miami Medical Investors Conference on Friday, November 12, 2010, at 1:00 pm ET. The conference is being held at the JW Marriot Marquis in Miami, Florida.
Read more »
Multicenter, Open-label Trial to Target Platinum-Sensitive Ovarian-Cancer Patients
Dallas, TX and New York, NY, November 3, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has commenced a Phase 2 combination trial for its second generation DACH-platinum cancer drug, ProLindac, in platinum-sensitive ovarian-cancer patients. This trial is an open-label, Phase 2 study of ProLindac given intravenously with paclitaxel. The combination trial will be conducted in up to eight European participating centers.
Read more »
Grants Cover ProLindac, Thiarabine, MuGard, CobOral Oral Insulin and CobaCyte siRNA Delivery Programs
Dallas, TX and New York, NY, November 1, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has been awarded $1.5 million in government grants. Under the recently enacted Patient Protection and Affordable Care Act, cash grants were awarded to Qualifying Therapeutic Discovery Projects that showed significant potential in producing new and cost-saving therapies, support job growth and increase U.S. competitiveness. Grants were awarded through a competitive application process, and seven out of eight Access Pharmaceutical applications were awarded.
Read more »
Digg!
Del.icio.us
MuGard's ready-to-use viscous liquid is tasteless, and is safe to swallow. See